July 13, 2016 10:56 AM EDTUpdated June 28, 12:32 PM
R&D
Special

The 15 top R&D spenders in the glob­al bio­phar­ma busi­ness: 2016

John Carroll

Editor & Founder

Just about every play­er on this list has trig­gered a ma­jor over­haul of R&D in the past decade
Over the past nine years that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

In­cyte’s bet on Escient hits a snag as safe­ty is­sues ham­per Phase 2 chron­ic hives tri­al

For­mer NCI di­rec­tor teams up with se­r­i­al en­tre­pre­neur for $70M VC fund tar­get­ing 'su­per-ear­ly' sci­ence

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times